Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085601 | 0.86 | LMNA (0.40) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL513295 | 0.85 | LMNA (0.50) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL20085598 | 0.81 | ALDH1A1 (0.40) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL370158 | 0.80 | MAPT (0.42) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL361238 | 0.80 | ALDH1A1 (0.47) | LMNAHTTMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL361843 | 0.79 | MAPT (0.41) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL361807 | 0.79 | IDO1 (0.38) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL3428571 | 0.79 | HTT (0.49) | LMNAHTTMAPTSMN1; SMN2MAPK1 | |
| SCHEMBL29637085 | 0.79 | NR4A1 (0.36) | LMNAMAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17142092 | 0.79 | NR4A1 (0.36) | LMNAMAPTSMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833454-B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833454-B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833454-B2 | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-29 | — | — | US | disclosed |
| EP-3126355-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153709-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015153709-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182050-A1 | DIFLUOROMETHOXY COMPOUND WITH LOW BIOACTIVATION POTENTIAL FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, BACE2 | LMNA 1440/4885HTT 72/4885MAPT 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.